



MARKET RELEASE

17 May 2017

SIRTEX MEDICAL LIMITED

TRADING HALT

The securities of Sirtex Medical Limited (the “Company”) will be placed in Trading Halt Session State at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in Trading Halt Session State until the earlier of the commencement of normal trading on Friday, 19 May 2017 or when the announcement is released to the market.

Security Code: SRX

Kimberley Brown
PRINCIPAL ADVISER, LISTINGS COMPLIANCE (SYDNEY)



Sirtex Medical Ltd
ABN 35 078 166 122
Level 33
101 Miller Street
North Sydney, 2060
Phone +61 2 9964 8420
www.sirtex.com

17th May 2017

Kimberley Brown
ASX Limited
Exchange Centre
20 Bridge Street
Sydney, NSW, 2000

BY EMAIL: kimberley.brown@asx.com.au; tradinghaltssydney@asx.com.au

Dear Kimberley

Trading Halt Request

In accordance with ASX Listing Rule 17.1, Sirtex Medical Limited (**Company**) requests an immediate trading halt in the shares of the Company.

The trading halt is requested to provide the Company sufficient time to review and assess the implications on the business of the soon to be released clinical data relating to the SIRFLOX/FOXFIRE/FOXFIRE Global and SIRveNIB clinical studies at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, USA. The Company believes that this information will be material.

The Company requests that the trading halt remain in place until the earlier of an announcement to the market or the commencement of normal trading on Friday, 19th May 2017.

The Company is not aware of any reason why the trading halt should not be granted, nor is it aware of any other information necessary to inform the market about the trading halt.

Yours sincerely

A handwritten signature in black ink, appearing to read "Darren Smith", with a long horizontal flourish extending to the right.

Darren Smith
Chief Financial Officer and Company Secretary
Sirtex Medical Limited